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Résumé en
anglais
Memantine is a symptomatic treatment that partially prevents cognitive decline in
Alzheimer disease (AD). The neuroprotective effects of memantine and vitamin D may
potentiate each other, with benefits for cognition. The objective of this
exposed/unexposed pilot study was to determine the cognitive changes among AD
patients using memantine according to the presence or absence of vitamin D
deficiency (VDD). Fifty-eight AD patients followed in a memory clinic during 6 months
between 2009 and 2014 (mean±standard deviation, 82.9±5.0years; 56.9%female) were
separated into four groups according to VDD (i.e., serum 25-hydroxyvitamin D≤25nM)
at M0 and M6 (i.e., Group 1: no VDD-M0, no VDD-M6; Group 2: VDD-M0, no VDD-M6;
Group 3: no VDD-M0, VDD-M6; Group 4: VDD-M0, VDD-M6). The 6-month cognitive
change was examined with the Mini-Mental State Examination (MMSE) score in the 4
groups according to the use of memantine. Age, gender, body mass index, IADL score,
GDS score, and use of pchychoactive drugs were measured at baseline. We found that
participants using memantine had a lower MMSE score at M0 compared to those
without memantine (P=0.006). After 6 months of follow-up, there was a memantine-
related improvement of the MMSE score only in the participants with VDD-M6. This
was significant in Group 3 with no VDD-M0 (P=0.039), but not in Group 4 who already
had VDD-M0. Similarly, using memantine was associated with a 6-month improvement
of MMSE only in Group 3 in whom VDD appeared during the follow-up (β=8.8,
P=0.044). In conclusion, the use of memantine was associated with improved cognitive
performance after 6 months of treatment in the presence of VDD at M6. Memantine
may prevent the cognitive decline that accompanies the onset of VDD, which prompts
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